Irritable Bowel Syndrome Stories
Irritable bowel syndrome (IBS) is a common problem with the intestines. IBS is a health problem that is often ignored and whose real cause is yet to be found.
Salix announces FDA acceptance for filing and priority review designation for Xifaxan550 sNDA for the treatment of non-constipation irritable bowel syndrome
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Company's efficacy supplement to the New Drug Application (NDA) for XIFAXANÂ® (rifaximin) 550 mg tablets for the proposed indication of treatment of nonâ€“constipation irritable bowel syndrome (Nonâ€“C IBS) and IBSâ€“related bloating. People aged over 50 are at a higher risk of contacting the inflammatory intestinal disease ulcerative colitis remission compared to youngsters who suffered the diseases, according to data provided by a new study conducted in the United States.